Government Affairs
Refine Search
Pharmaceutical
The introduction of a new 40% R&D tax credit will help keep Australia at the forefront of medical research, said the drug industry trade group Medicines Australia chief executive Brendan Shaw, welcoming the Senate Economics Committee's recommendation that the new R&D tax credit be implemented before the end of June. 18 June 2010
Pharmaceutical
Efforts to improve the health of poor people in the developing world by increasing the availability of drugs to treat diseases such as malaria, HIV, and tuberculosis are having a serious unintended side effect: accelerated drug resistance, which is raising costs and claiming lives. 16 June 2010
Pharmaceutical
The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) this week delivered a formal statement to the United Nations General Assembly Hearings with non-governmental organizations (NGOs), civil society and the private sector on the UN Millennium Development Goals. 16 June 2010
Pharmaceutical
Danish insulin giant Novo Nordisk appears to have backed down in its fight with the Greek government over the draconian drug price cuts - averaging 25% - imposed, which led to the company (as well as fellow Denmark-based LEO Pharma) to say that it would not supply some of its products (the so-called modern insulins or insulin analogues) to the country as it would not only be uneconomic, but would likely lead to parallel trading and calls for reductions in other markets (The Pharma Letter June 1). 15 June 2010
Pharmaceutical
The US House Oversight and Government Reform Committee, under the chairmanship of Representative Edolphus 'Ed' Towns (Democrat, New York), on Friday launched an investigation into Wyeth Pharmaceuticals (now part of global drugs behemoth Pfizer), citing reports alleging the company illegally promoted the kidney transplant drug Rapamune (sirolimus) for indications not approved by the Food and Drug Administration, and specifically targeted African-Americans in its promotional activities. 14 June 2010
Generics
Government intervention in prescription drug markets in Canada produces no overall cost-savings for consumers, compared to relatively more free market-based policy approaches in the USA, concludes a new report from the Fraser Institute, Canada's leading public policy think-tank. 14 June 2010
Pharmaceutical
In yet another negative ruling for an expensive cancer treatment, the UK's National Institute for Health and Clinical Excellence (NICE) this morning issued its Final Appraisal Determination (FAD) advising against National Health Service funding for drug giant GlaxoSmithKline's oral Tyverb (lapatinib) in combination with Roche's Xeloda (capecitabine) for the treatment of an aggressive form of advanced breast cancer (ErbB2/HER 2-positive). 10 June 2010
Pharmaceutical
Speaking at the Detroit Economic Club yesterday, John Lechleiter, chairman, president and chief executive of US drug major of Eli Lilly, warned that America's greatest competitive advantage - its "genius for innovation" - is in jeopardy. His speech focused on the USA's historic leadership in innovation and the policies necessary to ensure America does not fall behind as other countries gain momentum in the life sciences. 10 June 2010
Pharmaceutical
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) today approved a 'Joint Industry Position on the Publication of Clinical Trial Results in the Scientific Literature,' previously approved by the European Federation of Pharmaceutical Industries and Associations (EFPIA), the Japanese Pharmaceutical Manufacturers Association (JPMA) and the Pharmaceutical Research and Manufacturers of America (PhRMA) and the IFPMA's council (The Pharma Letter November 11, 2009). 10 June 2010
Pharmaceutical
Already impacted by draconian drug price cuts, R&D-based drugmakers in Turkey say they are facing another peril, in that patent infringers will enjoy impunity from penalty unless there is enactment of new legislation. 9 June 2010
Generics
'Increasing generic medicines market penetration is the fastest way towards considerable and sustainable savings for health care systems in Europe'. This is the key message delivered by European Generics medicine Association (EGA) president Didier Barret to delegates at the group's annual general meeting in Rome, Italy, last week. 9 June 2010
Pharmaceutical
The handling of the H1N1 pandemic by the World Health Organization (WHO), European Union agencies and national governments led to a 'waste of large sums of public money, and unjustified scares and fears about the health risks faced by the European public,' according to a report by the Social, Health and Family Affairs Committee of the Parliamentary Assembly of the Council of Europe (PACE) made public last week in Paris, France. 8 June 2010
Pharmaceutical
Some people learn from others' mistakes, and some have to "learn the hard way." Will America follow the lead of countries who have actually tried their own version of ObamaCare, or could we still learn from their mistakes? asks Alieta Eck, a New Jersey, USA, physician who has been in private practice in Piscataway since 1988 and involved in health care reform since residency. 8 June 2010
Pharmaceutical
The multiple sclerosis drug risk sharing scheme that has been used in the UK is "a costly failure" and should not be continued, according to researchers writing on bmj.com last week. They argue that the biggest losers are the other National Health Service patients who would otherwise have benefited from the money spent on the scheme, estimated to be around 50 million ($72.3 million) per year since it was set up in 2002. 7 June 2010
Pharmaceutical
Developing countries in Africa, Asia and Latin America - spearheaded by India and Brazil - have secured passage of a resolution that calls for a major review of the World Health Organization's role in combating counterfeit and substandard drugs. The demands seek to curtail the role of the WHO in intellectual property enforcement issues and to prioritize public health concerns. 7 June 2010
Biotechnology
Elan, the troubled Irish biotechnology firm that has witnessed considerable turbulence and extensive restructuring in recent years, is to part company with its oft criticized chief executive, Kelly Martin, but not for another two years, but even then he will have another year as adviser. 4 June 2010
Generics
Pharmaceutical companies in Europe are seeing their worst fears being realized after first Germany, then Greece and Spain imposed swinging drug price cuts (The Pharma Letters passim), two more - France and Italy - have announced similar action, aiming to reduce their health care spending and cut budget deficits. 3 June 2010
Pharmaceutical
The governing bodies of Spain's drug industry association Farmaindustria met in an extraordinary session last week to assess the impacts regarding the package of measures on pharmaceutical expenditure which was approved by the Council of Ministers, and the lobby group has called for a meeting with the Prime Minister. 3 June 2010
Biotechnology
The chief executive of the UK Biotechnology Industry Association (BIA), Nigel Gaymond, reported on progress being made by the group, saying that 'one of the exciting offshoots of our work with the Office for Life Sciences (OLS) has been the increased working relationships we have had with sister organizations representing the extended gamut of the biomedically-oriented sector - pharmaceuticals, biotech, diagnostics and devices.' 2 June 2010
Pharmaceutical
The Irish Pharmaceutical Healthcare Association (IPHA) has welcomed the publication of the Clinical Research Roadmap by the Irish Clinical Research Infrastructure Network (ICRIN) which defines the necessary steps Ireland needs to take to create a sustainable national system to support clinical research. 2 June 2010
Pharmaceutical
The nomination of Robert F Kennedy Jr — known as RFK Jr — for the role of US Secretary of the Department of Health and Human Services (HHS) President-elect Donald Trump sent shares in vaccine companies sharply downwards. 22 November 2024
article
The UK government has reappointed BioIndustry Association (BIA) chairman Daniel Mahony as its Life Sciences Investment Envoy. 21 November 2024
Pharmaceutical
The Danish government’s newly-unveiled health reform has been praised for tackling chronic disease care and health inequalities while driving health innovation. 18 November 2024
Pharmaceutical
New research published by the European Federation of Pharmaceutical Industries and Associations (EFPIA) provides in-depth analysis of the economic footprint of the pharmaceutical industry in Europe, across member states and compares Europe to other regions of the world. 18 November 2024
Pharmaceutical
Johnson & Johnson has taken legal action to defend a contentious rebate initiative, filing a lawsuit in the US District Court for the District of Columbia. 15 November 2024
Pharmaceutical
The share prices of Pfizer, GSK, Novavax and other vaccine companies were all markedly lower on Friday. This was not due to the publication of disappointing research results in the sphere, or an ominous stance taken by a major regulator on a key filing, but rather a political development that could spell trouble for the vaccines field as a whole. 15 November 2024
Biotechnology
BeiGene has announced plans to rebrand as BeOne Medicines, a move the cancer specialist says reflects its commitment to fighting cancer through collaboration. 15 November 2024
Pharmaceutical
Danish patients are being offered fewer innovative treatments than Norwegians and Swedes, a new estimate from the Danish Medicines Council shows. 11 November 2024
Pharmaceutical
According to the Swedish pharma trade group Lif, it is positive that, in the updated life science strategy, the government expresses an ambition for Sweden to become more attractive for research investments. 11 November 2024
Pharmaceutical
Li Li, Commissioner of China's National Medical Products Administration (NMPA), and Mette Aaboe Hansen, interim director general of Danish Medicines Agency, have signed a letter of intent to promote bilateral cooperation in regulation of drugs and medical devices. 11 November 2024
Pharmaceutical
Following the news that Donald Trump is the winner of the 2024 US Presidential Election, Morningstar Equity analyst Julie Utterback has published a new note about the impact of this on the managed-care industry. 7 November 2024
Pharmaceutical
UK pharma major AstraZeneca, which has invested heavily in China, hosted a sell-side analyst call on Wednesday (November 6) to discuss the recent media reports about ongoing investigations in China. 7 November 2024
Pharmaceutical
Some of the UK’s leading academics and industry professionals have welcomed Chancellor Rachel Reeves’ £520 million ($669 million) pledge to develop the country’s medicine manufacturing capabilities. 6 November 2024
Pharmaceutical
European regulators will decide by December 6 whether Novo Holdings, the controlling shareholder of Danish pharma giant Novo Nordisk, can finalize its $16.5 billion acquisition of contract drug manufacturer Catalent. 5 November 2024
Pharmaceutical
The Danish government is rolling out the red carpet and welcomes several pharmaceutical companies. 4 November 2024
Generics
Medicines for Europe has launched a study of market barriers faced by European generics and biosimilar pharmaceutical companies operating in 11 key third-country markets. 31 October 2024
Pharmaceutical
Following the first Labour budget for 14 years, the Association of the British Pharmaceutical Industry (ABPI) welcomes Chancellor Rachel Reeves’ measures to improve UK life sciences competitiveness. 30 October 2024
Pharmaceutical
HOPO Therapeutics has been awarded a contract valued at up to $226 million from the Biomedical Advanced Research and Development Authority (BARDA). 29 October 2024
Pharmaceutical
The Danish government has presented part of the plan for a future life science strategy, which has been welcomed by the industry. 28 October 2024
Biotechnology
Legend Biotech has removed Genscript Biotech as its majority shareholder, in a move coinciding with rising US concerns over Chinese ties within the biotech sector. 24 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze